<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449199</url>
  </required_header>
  <id_info>
    <org_study_id>TMX-049DN-201</org_study_id>
    <nct_id>NCT03449199</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teijin America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teijin America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the effect of 2 dose levels of TMX-049 on
      urinary albumin excretion in subjects with Type 2 diabetes and albuminuria (a urinary
      albumin-to-creatinine ratio (UACR) 200 to 3000 mg/g and an estimated glomerular filtration
      rate (eGFR) ≥30 ml/min/1.73m2). Effects of each TMX-049 dose on UACR will be assessed in
      terms of ratios using log-transformed UACR at Baseline and after a 12-week period of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in log-transformed urinary albumin-to-creatinine ratio (UACR)</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with &gt;30% reduction in UACR</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kidney injury molecule 1 (KIM-1)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver fatty acid binding protein (L-FABP)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 8 hydroxy 2' deoxyguanosine (8-OHdG)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-acetyl-β-D-glucosaminidase (NAG)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Soluble tumor necrosis factor receptor 1 (sTNFR1)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity C reactive protein; (hs-CRP)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum uric acid (sUA)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>TMX-049 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TMX-049 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TMX-049 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMX-049</intervention_name>
    <description>A certain dose of TMX-049 to be taken orally, once daily</description>
    <arm_group_label>TMX-049 dose 1</arm_group_label>
    <arm_group_label>TMX-049 dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to be taken orally, once daily</description>
    <arm_group_label>TMX-049 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes treated with ≥1 glucose-lowering medication for at least 12 months

          -  UACR 200 to 3000 mg/g

          -  eGFR ≥30 ml/min/1.73m2

          -  Treated with at least the minimal recommended dose of an angiotensin converting enzyme
             inhibitor (ACEI) or an angiotensin II receptor blocker (ARB), but not both

        Exclusion Criteria:

          -  History of Type 1 diabetes

          -  Women who are breast feeding

          -  Treatment with any uric acid-lowering therapy within previous 2 weeks

          -  History of intolerance to any XO inhibitor

          -  History of a gout flare requiring pharmacologic treatment

          -  History or presence of tophaceous gout

          -  History of immunosuppressant treatment for any known or suspected renal disorder

          -  History of a non-diabetic form of renal disease

          -  Glycosylated hemoglobin (HbA1c) &gt;11%

          -  sUA &lt;4.0 mg/dL or &gt;10.0 mg/dL

          -  Positive urinary pregnancy test

          -  Dialysis for acute renal failure within previous 6 months

          -  Renal allograft in place or a scheduled kidney transplant within the next 22 weeks

          -  Congenital or acquired solitary kidney
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Teijin America, Inc. Contact</last_name>
    <phone>+1-212-308-8744</phone>
    <email>clinical-trials-contact@teijinpo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Solaris Clinical Research, Llc</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carl R. Meisner Medical Clinic, PLLC</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

